



RECEIVED

MAY 10 2001

TECH CENTER 1600/2900

VIA HAND DELIVERY MAY 8, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1646
Box Seq 2

Application of: Coleman et al.

Attorney Docket No.: PF206D1

Application Serial No.: 08/972,301

Art Unit: 1646

Filed: November 18, 1997

Examiner: Kemmerer, E.

Title: Endothelial Monocyte Activating Polypeptide III

29/G
M.J.J
5/15/01

AMENDMENT AND RESPONSE TO COMMUNICATION

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits, and in response to the Communication mailed on April 23, 2001 (Paper No. 28), Applicants respectfully request entry and consideration of the following amendment and remarks. Applicants submit concurrently herewith (a) a Third Substitute Sequence Listing in both paper and computer readable form; (b) a Statement Under 37 C.F.R. §§ 1.821 and 1.825; and (c) a copy of the Notice to Comply (Paper No. 28). Please amend the application as follows:

In the Sequence Listing:

Please cancel the Second Substitute Sequence Listing filed on March 9, 2001. Please append the paper copy of the Third Substitute Sequence Listing submitted herewith to the end of the present application and renumber the pages of the application accordingly.